Moleculin reports pooled analysis shows no cardiotoxicity signal for Annamycin in five trials
MBRX•Moleculin Biotech reported that a pooled analysis of five Annamycin trials involving 90 patients found no signs of treatment-related heart damage.
1. Pooled trial findings
The peer-reviewed analysis pooled data from five Annamycin trials involving 90 patients with acute myeloid leukemia or metastatic soft tissue sarcoma. It found no signs of treatment-related heart damage.
2. Development context
The findings, published in Frontiers in Cardiovascular Medicine, had previously been presented in clinical updates and were reinforced by an independent Cleveland Clinic cardio-oncology review. Moleculin said the results support continued development in the MIRACLE program for relapsed or refractory AML.
